Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D3.100 - Assessment of the impact of psychotropic drugs, antihistamines, and corticosteroids on the interpretation of skin tests in allergology
D3.101 - Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates
D3.93 - Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan
D3.106 - Real-life outcomes of rapid drug desensitization to taxanes
D3.94 - Good Practice Recommendations for Basophil Activation Test (BAT) Data Analysis in Routine and High-Background Settings
D3.95 - Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances
D3.96 - High burden of latent aeroallergen sensitization in healthy urban medical students: a blinded skin prick test study from South India
D3.97 - Allergic contact dermatitis confirmed by repeated open application test in a 68‑year‑old patient
D3.98 - An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology
D3.104 - Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform
D3.105 - Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy
D3.107 - Comparison of Cupressaceae sensitization allergens in a large Spanish cohort
D3.103 - Comprehensive Allergen Characterization for Standardized Basophil Activation Testing
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download